US stocks rise amid recovery bets, FDA approval - BNN

U.S. equities rose Monday as the COVID-19 immunization drive was bolstered by U.S. regulators granting full approval for the vaccine made by Pfizer Inc. and BioNTech SE.

The S&P 500 and Nasdaq 100 rebounded from lows last week as the approval could lead to more vaccine mandates amid a surge in delta variant cases that has threatened the momentum of the global economic recovery. Mixed U.S. data Monday showed July home sales coming in higher than expected while growth at U.S. services and factories slowed to an eight-month low.

Energy shares led the gains as oil rose above US$65 a barrel in New York on improving sentiment. Treasuries were little changed and the dollar was weaker as investors also looked ahead to the Jackson Hole symposium Thursday, which may offer insights into how and when the Federal Reserve plans to taper bond purchases.

“Amid another record high last Monday it’s remarkable that we’re looking to start the week yet again on the upside,” said Chris Larkin, managing director of trading at E*Trade Financial. “The gains last week couldn’t make up for the losses following the Fed confirming its intentions to taper its purchasing program. All eyes will remain on the Fed as investors will be looking for more guidance on the taper from Powell’s speech at Jackson Hole.”

Dallas Fed President Robert Kaplan said he’s open to adjusting his view that the Fed should start tapering its asset-purchase program sooner rather than later, if the delta strain persists. Meanwhile, Treasury Secretary Janet Yellen endorsed Jerome Powell for a second term as Fed chair, a move that could reduce uncertainty about the path for monetary policy.

“Solid economic and corporate profit growth, in conjunction with a still-accommodative Fed, means that the environment for stocks remains favorable,” said David Lefkowitz, head of equities Americas at UBS Global Wealth Management. “As a result of our higher EPS estimates, we raise our targets for the S&P 500 for December 2021 by 100 points to 4,600 and June 2022 by 150 points to 4,800. We initiate our December 2022 target of 5,000, representing about 13 per cent price appreciation from current levels.”

Aside from Fed commentary, traders will be looking for the latest U.S. data on manufacturing, gross domestic product and jobs this week. The U.S. House of Representatives will also be holding key votes related to President Joe Biden’s US$4.1 trillion economic agenda.

In Europe, the Stoxx Europe 600 index increased for a second day. In Asia, equities in China and Japan also gained. China has once again brought local COVID-19 cases down to zero.

Here are some events to watch this week:

• U.S. Markit manufacturing PMI and existing home sales Monday
• Bank of Korea policy decision; briefing by Governor Lee Ju-yeol Thursday
• Fed officials attend the Jackson Hole Economic Policy Symposium from Thursday through Saturday
• U.S. GDP, initial jobless claims Thursday
• July U.S. personal income and spending data Friday. Investors will scrutinize the personal consumption expenditures price index, an inflation measure closely watched by the Fed.

Some of the main moves in markets:

Stocks

• The S&P 500 rose 0.9 per cent as of 4:01 p.m. New York time
• The Nasdaq 100 rose 1.5 per cent
• The Dow Jones Industrial Average rose 0.6 per cent
• The MSCI World index rose 1.1 per cent

Currencies

• The Bloomberg Dollar Spot Index fell 0.5 per cent
• The euro rose 0.4 per cent to US$1.1748
• The British pound rose 0.8 per cent to US$1.3731
• The Japanese yen rose 0.1 per cent to 109.67 per dollar

Bonds

• The yield on 10-year Treasuries was little changed at 1.25 per cent
• Germany’s 10-year yield advanced one basis point to -0.48 per cent
• Britain’s 10-year yield advanced one basis point to 0.53 per cent

Commodities

• West Texas Intermediate crude rose 5.3 per cent to US$65.44 a barrel
• Gold futures rose 1.3 per cent to US$1,807.40 an ounce

Adblock test (Why?)

US stocks rise amid recovery bets, FDA approval - BNN
Read More